Dr. Wierda Discusses the Role of Ibrutinib in CLL

William G. Wierda, MD, PhD
Published: Wednesday, Oct 11, 2017



William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Considering all the progress being made with novel therapies in this disease, ibrutinib remains a vital part of frontline treatment for patients with CLL, says Wierda.

Currently, trials investigating dosing are aiming to determine whether a lower dose of ibrutinib may be as effective or better tolerated than 420 mg.
 


William G. Wierda, MD, PhD, medical director of the Leukemia Center at The University of Texas MD Anderson Cancer Center, discusses the role of ibrutinib (Imbruvica) in the treatment of patients with chronic lymphocytic leukemia (CLL).

Considering all the progress being made with novel therapies in this disease, ibrutinib remains a vital part of frontline treatment for patients with CLL, says Wierda.

Currently, trials investigating dosing are aiming to determine whether a lower dose of ibrutinib may be as effective or better tolerated than 420 mg.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x